PTSD in soldiers is primarily treated with trauma-focused psychotherapy, sometimes combined with medication. The most effective approaches are talk therapies that directly process traumatic memories, and about 53% to 68% of service members who go through these treatments no longer meet the criteria for PTSD afterward. The specific path depends on symptom severity, personal preference, and what format a veteran can commit to.
Trauma-Focused Talk Therapy
The frontline treatments for military PTSD are therapies that help you revisit and reprocess traumatic experiences rather than avoid them. Three stand out as the most studied and widely offered through the VA and military treatment facilities.
Prolonged Exposure (PE) works by having you gradually confront trauma-related memories and situations you’ve been avoiding. You’ll talk through the traumatic event in detail during sessions and practice approaching safe situations in daily life that you’ve been steering clear of. Among those who complete PE, about 68% no longer meet diagnostic criteria for PTSD. Long-term data is even more encouraging: 83% of patients who received PE no longer qualified for a PTSD diagnosis six years after treatment.
Cognitive Processing Therapy (CPT) takes a different angle. Instead of repeatedly revisiting the trauma itself, CPT focuses on how you think about what happened. It helps you identify and challenge stuck points, the beliefs that formed during or after the trauma (“I should have done something,” “The world is never safe”) that keep symptoms locked in place. CPT typically runs 12 sessions.
Eye Movement Desensitization and Reprocessing (EMDR) has you briefly focus on the traumatic memory while following a side-to-side visual stimulus, like the therapist’s moving finger. The mechanism isn’t fully understood, but it appears to help the brain reprocess traumatic memories so they lose their emotional charge. EMDR produces outcomes comparable to PE and CPT in clinical trials.
Why Many Veterans Don’t Finish Treatment
These therapies work well for those who complete them, but completion is a real problem. A large meta-analysis covering more than 124,000 military clients found that the overall dropout rate across PTSD treatments was about 26%. The most effective trauma-focused therapies had the highest dropout: weekly CPT lost 40% of participants, and weekly PE lost about 35%. The therapies ask you to face the thing your brain has been working hard to avoid, which is inherently difficult. Logistical barriers matter too. Weekly sessions over three to four months can clash with military duties, family obligations, or the simple reality of living far from a VA facility.
Treatments that were less emotionally intensive had lower dropout. Present-centered therapy, which focuses on current problems rather than directly reprocessing trauma, lost only about 16% of participants. Mindfulness-based stress reduction had a similar retention rate of around 17%.
Intensive Programs That Compress Treatment
One of the most promising developments in military PTSD care is the intensive outpatient program, or IOP. Instead of spreading therapy across months of weekly appointments, IOPs deliver the same evidence-based treatments (PE or CPT) over two to four weeks of daily sessions. You show up five days a week and complete 10 to 12 therapy sessions in that compressed window.
The results are striking. In VA-run IOPs, 87% of veterans completed the program, a dramatic improvement over the 60% to 65% completion rates seen in traditional weekly formats. Nearly 80% of those who finished showed a clinically meaningful reduction in PTSD symptoms. The two-week track produced a 25-point average drop on the standard PTSD symptom scale, which represents a major shift in daily functioning. Outcomes were comparable whether veterans chose the two-week or four-week track, and whether they did PE or CPT.
IOPs work partly because they remove the opportunity to drift away between sessions. The momentum builds quickly, and the concentrated format may actually make it easier to stay engaged with difficult emotional material rather than spending a week dreading the next appointment.
Medications for PTSD
Two antidepressants have FDA approval specifically for PTSD: sertraline (Zoloft) and paroxetine (Paxil). Both are SSRIs, a class of medications that increase the availability of serotonin in the brain. They can reduce the overall intensity of PTSD symptoms, including intrusive thoughts, emotional numbness, and hyperarousal. Sertraline is typically prescribed at 50 to 200 mg daily, and paroxetine at 20 to 60 mg daily.
Venlafaxine, which works on both serotonin and norepinephrine, is also strongly recommended by VA treatment guidelines, though it isn’t specifically FDA-approved for PTSD. Medications are often used alongside therapy rather than as a standalone treatment. They can take the edge off symptoms enough that engaging in trauma-focused therapy becomes more manageable.
Nightmares and Sleep Problems
Combat-related nightmares are one of the most disruptive PTSD symptoms, and they don’t always respond well to standard antidepressants. Prazosin, a blood pressure medication, has been used off-label to target trauma nightmares specifically. It works by blocking the adrenaline-related signaling that fuels the body’s fight-or-flight response during sleep. VA guidelines recommend it for nightmares and sleep disturbance, though the clinical evidence is mixed. Several smaller trials showed clear benefits, but a larger randomized controlled trial found no significant improvement in nightmare frequency compared to a placebo. If your provider suggests trying it, dosing usually starts low (1 mg at bedtime) and gradually increases over several weeks based on response.
Virtual Reality Exposure Therapy
Virtual reality exposure therapy, or VRET, uses computer-generated combat environments to help veterans revisit traumatic events in a controlled setting. The scenarios are developed with input from combat veterans and include dynamic, multisensory elements designed to feel realistic. For some veterans who struggle with the purely imagination-based approach of standard prolonged exposure, having a visual and auditory environment to anchor the experience can make it easier to engage.
In head-to-head trials, VRET performs about as well as traditional prolonged exposure. No significant advantages have been found in either direction, and both produce earlier reductions in avoidance and hyperarousal symptoms compared to no treatment. Both approaches also reduce suicidal ideation. VRET may be particularly useful for veterans who have difficulty generating vivid mental imagery on their own or who haven’t responded to conventional therapy.
Service Dogs
Pairing a veteran with a trained psychiatric service dog is an increasingly recognized complement to standard PTSD treatment. An NIH-supported study found that veterans who received service dogs reported significantly lower PTSD symptom severity after three months compared to those on a waitlist. They also had less anxiety, less depression, and reduced social isolation, with higher feelings of companionship. Service dogs can be trained to perform specific tasks like waking a veteran from nightmares, creating physical space in crowds, or providing grounding during flashbacks. They don’t replace therapy or medication, but they address the day-to-day quality-of-life challenges that clinical treatments sometimes leave behind.
Stellate Ganglion Block
This is a newer, more experimental approach. A stellate ganglion block (SGB) involves injecting a local anesthetic into a bundle of nerves in the neck that’s part of the body’s fight-or-flight system. The idea is to essentially reset an overactive stress response. Early case studies reported rapid improvement in 70% to 75% of veterans, with some noticing changes within minutes to days. However, a more rigorous randomized controlled trial tempered that enthusiasm: PTSD symptom improvement was only 5% to 15% after the first injection and 12% to 21% after a second, which was no better than a sham injection of saline. SGB is still being studied and isn’t a standard recommendation, but some military treatment facilities offer it, particularly for veterans who haven’t responded to other approaches.
MDMA-Assisted Therapy
Phase 3 clinical trials of MDMA-assisted therapy showed that nearly 70% of participants no longer met PTSD diagnostic criteria after treatment, results that generated significant attention in the veteran community. The FDA granted it breakthrough therapy status in 2017. However, in 2024, the FDA declined to approve it, citing problems with how the trials were designed, including difficulties with blinding (participants could often tell whether they’d received MDMA or a placebo), incomplete safety assessments, and allegations of potential misconduct. This means MDMA-assisted therapy is not currently available as a legal treatment option outside of clinical trials, though advocacy and research efforts continue.